Navigation Links
Diabetes Linked to Higher Parkinson's Risk

or how many calories their bodies absorb -- can reduce insulin resistance and improve beta cell function in severely obese people, regardless of whether they lose any weight, according to a study by researchers in Italy.

With the number of obese people rising rapidly in the U.S. and around the world, bariatric surgery has been growing in popularity. Previous research has shown this surgery can restore glucose tolerance in the majority of severely obese people. But this study found it could also improve beta cell function, regardless of how much weight a person does or doesn't lose after surgery.

Obesity greatly increases a person's risk of developing type 2 diabetes, which is characterized by insulin resistance and impaired beta cell function.

"Why these surgeries would improve beta cell function and glucose tolerance, independent of weight loss, remains unclear," said lead researcher Dr. Ele Ferrannini, Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa School of Medicine, Italy. "But obviously the fact that it does improve beta-cell function could make bariatric surgery a useful tool in the prevention of diabetes in the severely obese patient."

Note: ADA clinical practice guidelines recommend that bariatric surgery may be considered for some individuals with type 2 diabetes who also have a BMI of 35 or higher. While this can result in marked improvements in glycemia, the long-term benefits and risks of bariatric surgery in individuals with pre-diabetes and diabetes continue to be studied.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into the nation's fifth leading cause of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations. For more information about diabetes, visit the American Diabetes Asso
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Diabetes Linked Higher Parkinson Risk
(Date:10/13/2008)... from Multiple Cancer Populations Facilitates ..., Mich., Oct. 13 /- Rubicon Genomics,...rick to amplify DNA samples for The,Cancer Atlas G...amplify and standardize total genomic,DNA from 3,0...The Rubicon,GenomePlex(TM) Whole Genome Amplificat...
(Date:10/12/2008)...lone and in Combination with Chemotherapy, FREMON...icals, Inc., a,development-stage pharmaceutical co...rence (RNAi)-based therapeutics, today announced t...on efficacy of siRNA targeting,its proprietary tar...) in,the edition dated October 1, 2008. The paper,...
(Date:10/12/2008)...NGTON, Oct. 12 /- Boston,Sc... results from an analysis,of nearly 7,500 patients...re designed to confirm the performance of the TAXU...t System in real-world practice. The,two-year pool... clinical,restenosis in patients with diabetes as ...
(Date:10/10/2008)...t. 10 /- Diplomat Specialty,Pharmacy ...d Diplomat,Specialty Pharmacy to be one of only th...l Therapy Optimization Study for Multiple Sclerosi...dy, is to examine the benefits of a,specialty phar...erence and,patient outcomes. Targeted patient outc...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 1Allscripts to Announce First Quarter 2008 Results on April 30 17431 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 1Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 2Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 4DURECT to Participate in Morgan Stanley Global Healthcare Conference 17424 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 2
... 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics...ase III multi- center clinical studies of ferumoxy... will be presented during,the National Kidney Foun...place April 10th through 14th in Orlando, Florida....be presented on,Wednesday, April 11, 2007 at appro...
...wed Complete Response or Reduction of,Lesion Size ... 05, 2007 /PRNewswire-FirstCall/ - Nventa,Biopharm...ation of,positive results from a clinical trial ex...spE7, an investigational therapeutic,vaccine for h...en,with the highest grade of cervical dysplasia (C...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6
(Date:10/10/2008)...gency of Record, CHICAGO, Oct. 10 /PRNewswire/ --...e launch of its "Delivering Small Miracles" campai...ng commitment to providing the highest,level of se...ecial Care,Nursery and Mother/Baby units., The ca...c relations and,advertising via billboards, geogra...
(Date:10/10/2008)...tCall/ -- Synvista,Therapeutics, Inc. (Amex: SYI ...ederici, 49, to its Board of Directors, expanding ...est Pharmaceutical Services as Vice President and,...is financial leadership,West Pharmaceutical,s rev...00 million. He has more than 20 years of public ac...
(Date:10/10/2008)...tCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leadin...diagnostics, medical imaging systems and surgical ... of women, today announced plans to release its,fo...Tuesday, November 11,2008 after market close. In ... a conference call on Tuesday, November 11, 2008 a...
(Date:10/10/2008)... NuView Life Sciences Inc.,(NuView) has agreed to ...ce), including operations of the linear accelerato...exas. The Trace facility produces,Copper-64, Coppe...d in,molecular imaging and nuclear medicine. Paul ...e confident that by improving operational,efficien...
Breaking Medicine News(10 mins):Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 2Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 3Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2
...nity-built Riverina Cancer Care Centre is looking ... around reduction in prices, which will bring abou...ike. // This has happened following fears expresse...ople may avoid treatment owing to high costs. Kay ...
...hemselves on the plane to the gulf, not so much fo...s of people in the Gulf. // The demand for rabbit ...nd is much like the oasis in the desert, for what .... Gulf countries are exploring the options of imp...
... with birth defects is improved by incorporation o.... It has been known that folic acid supplementatio...rological birth defects such as spina bifida, anen... the effect of consumption of folic acid fortified...
...March issue of Paediatrics, Children's Hospital Bo...sumption of sugary drinks –home deliveries of nonc...ht loss. // Cara Ebbeling, PhD, and David Ludwig, ... Endocrinology, led the randomized, controlled tri...
Other Medicine News:Health News:A simple answer to teen weight loss: Reducing sugary drinks 2
Substrate Plasma for Factor XII Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XII.
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of Tissue Plasminogen Activator Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests.
Medicine Products: